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Abstract
Inflammation is one of main mechanisms of autoimmune disorders and a common feature of most diseases. Appropriate
suppression of inflammation is a key resolution to treat the diseases. Sirtuin1 (Sirt1) has been shown to play a role in
regulation of inflammation. Resveratrol, a potent Sirt1 activator, has anti-inflammation property. However, the detailed
mechanism is not fully understood. In this study, we investigated the anti-inflammation role of Sirt1 in NIH/3T3 fibroblast
cell line. Upregulation of matrix metalloproteinases 9 (MMP-9), interleukin-1beta (IL-1b), IL-6 and inducible nitric oxide
synthase (iNOS) were induced by tumor necrosis factor alpha (TNF-a) in 3T3 cells and resveratrol suppressed overexpression
of these pro-inflammatory molecules in a dose-dependent manner. Knockdown of Sirt1 by RNA interference caused 3T3
cells susceptible to TNF-a stimulation and diminished anti-inflammatory effect of resveratrol. We also explored potential
anti-inflammatory mechanisms of resveratrol. Resveratrol reduced NF-kB subunit RelA/p65 acetylation, which is notably
Sirt1 dependent. Resveratrol also attenuated phosphorylation of mammalian target of rapamycin (mTOR) and S6 ribosomal
protein (S6RP) while ameliorating inflammation. Our data demonstrate that resveratrol inhibits TNF-a-induced inflammation
via Sirt1. It suggests that Sirt1 is an efficient target for regulation of inflammation. This study provides insight on treatment
of inflammation-related diseases.
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Introduction
Autoimmune diseases such as rheumatoid arthritis and systemic
sclerosis are characterized by aseptic inflammation manifested
with upregulation of pro-inflammatory cytokines [1,2]. Increase of
cytokines further enhances and sustains inflammatory processes
and causes tissue damage [3,4]. Inhibition or neutralization of
cytokines suppresses inflammatory cascades and improves func-
tional recovery in experimental models [5,6]. In clinic, blockade of
TNF-a by anti-TNF-a antibodies notably reduces inflammation
and ameliorates clinical outcomes [7,8,9,10], suggesting that
cytokines play a central role in autoimmune diseases. Reduction
of cytokines production or suppression of their signaling is an
efficient therapeutic target.
Sirtuin 1 (Sirt1), a mammalian homolog of Sir2, is a NAD
+-
dependent class III histone deacetylase. It has been shown to be
involved in a variety of pathophysiological processes, such as anti-
inflammation, cell growth and metabolism modulation, anti-
carcinogen [11,12,13]. Sirt1 regulates pro-inflammatory mediator
[14,15,16]. Knockout or knockdown of Sirt1 gene leads to increase
of cytokines release whereas Sirt1 activation by its activators
inhibits productions of TNF-a, monocyte chemoattractant protein
1 (MCP-1) and IL-8 [14,15,16]. Furthermore, Sirt1 has inhibitory
effects in experimental chronic inflammatory diseases such as
chronic obstructive pulmonary disease and colitis [14,16,17].
Suppression of pro-inflammatory cytokines production by Sirt1 is
highly related to its negative regulation of NF-kB activity by
deacetylating of RelA/p65 subunit at lysine 310 [15].
Resveratrol (trans-3,49,5-trihydroxystilbene), a polyphenolic
phytoalexins, is a potent activator of Sirt1 [18]. Increase of
evidence indicates that resveratrol exerts an anti-inflammatory
property [19,20,21]. Resveratrol has a chondroprotective capacity
through suppressing the production of IL-1b and reactive oxygen
species (ROS) [22]. In human primary airway epithelial cells,
resveratrol inhibits cytokine-stimulated iNOS expression and
nitrite production [23]. Resveratrol also protects cartilage against
the development of experimentally induced inflammatory arthritis
[24]. Recent multiple lines of evidence demonstrate that
resveratrol inhibits inflammation via blockade of NF-kB tran-
scriptive activity [25,26,27]. Resveratrol decreases the expression
of NF-kB subunit RelA/p65 or attenuates translocation of p65
from the cytosol to the nucleus with stabilization of inhibitory IkB,
and further downregulates levels of TNF-a and cyclooxygenase-2
(COX-2) [19,28].
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[29]. In the present study, we investigated the inhibitory role of
Sirt1 in TNF-a induced cytokine production in fibroblast cells
through activating Sirt1 with resveratrol or downregulating Sirt1
by RNA interference. We further demonstrated that resveratrol
inhibited inflammation via a Sirt1-dependent manner.
Methods
Cell culture and treatment
Mouse embryonic 3T3/NIH fibroblasts (obtained from the
American Type Culture Collection) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with antibiotics
(100 U/ml penicillin, 100 mg/ml streptomycin) and 10% fetal
bovine serum, at 37uC in a humidified incubator with 5% CO2.
Recombinant mouse TNF-a (R&D System), resveratrol (Sigma) or
rapamycin (EMD4Bioscience) were used in this study.
Gelatin zymography
Gelatin zymography was done as previous described [30,31].
Briefly, culture media were collected after treatment and subjected
to SDS-PAGE in 10% polyacrylamide gels copolymerized with
1 mg/ml gelatin. After electrophoresis, gels were washed in
renature buffer to remove the SDS and further incubated with
developing buffer (Invitrogen) at 37uC for 24 hours. The gels then
were stained with Coomassie blue R-250 (Bio-Rad) for 15 minutes
followed by destaining in deionized water with 10% acetic acid
and 20% methanol. MMP-9 expression and proteolytic activity
were evidenced as clear bands against the background of stained
gelatin.
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-Hcl pH 7.4,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1%SDS, proteinase inhibitor (Roche) and phosphatase inhibitor
(Calbiochem) ). Protein concentration was detected using the
DC
TMprotein assay (Bio-Rad). Protein (30 mg) was loaded to 10%
SDS-PAGE and semi-dry transferred onto a Polyvinylidene
fluoride (PVDF) membrane. After blocking with 5% non-fat milk,
membranes were incubated overnight at 4uC with primary
antibodies against IL-1b (1:500, Santa Cruz), Sirt1(1:500, Milli-
pore), acetyl-NF-kBp65(Lys310) (1:500, Cell Signaling), phos-
phor(ser245/236)-S6RP (1:1000, Cell Signaling), phosphor
(ser2448)-mTOR (1:1000, Cell Signaling). Horseradish peroxidase-
conjugated secondary antibodies were used for ECL-plus (GE
Healthcare) detection. The results were normalized to b-actin
(1:5000, Abcam).
Real-time RT-PCR
Total RNA was extracted using RNAspin Mini Isolation Kit
(GE Healthcare), and reverse-transcribed into cDNA using the
SuperScripts III First-Strand Synthesis System (Invitrogen). The
genes were examined by real-time PCR. Primers were purchased
from Applied Biosystems (MMP-9, Mm00442991_m1; IL-6,
Mm00446190_m1; iNOS, Mm00440502_m1). Endogenous 18S
ribosomal RNA was used as internal control for normalizing gene
expression. Results then were assessed by t-test or ANOVA;
P#0.05 was considered to be statistically significant.
RNA interference
siRNA for mouse Sirt1 (ON-TARGETplus SMARTpool) was
purchased from Thermo Fisher Scientific and diluted in RNase-
free double distilled water (DDW). Cells were seeded on 6-well
plates. After 24 hours, cells at 60,70% confluency were
transfected with 20 nM Sirt1 siRNA, 20 nM control siRNA, or
the same volume of DDW for 6,8 hours using Lipofectamine
2000 according to the manufacturer’s protocol. Then cells were
switched into DMEM and incubated for 72 hours before
treatment.
Results
TNF-a induced overexpression of MMP-9 and other
inflammatory factors in fibroblasts
TNF-a induces inflammation in various cell types [20,32]. In
current study, we examined expressions of MMP-9, IL-6, iNOS
and IL-1b in TNF-a treated 3T3/NIH mouse embryonic
fibroblasts. Within 0.5 ng/ml to 10 ng/ml of dose rang, no cell
death was observed up to 72 hours after TNF-a treatment (data
not shown). As shown in figure 1, TNF-a induced notably MMP-9
upregulation in a dose- and time- dependent manner. The
concentration of 10 ng/ml of TNF-a was chosen for investigating
the response of fibroblasts to cytokine stimulation. Messenger
RNA expressions of MMP-9, iNOS and IL-6 were significantly
induced by TNF-a. IL-6 was increased strikingly as early as 30
minutes post treatment; while MMP-9 and iNOS were elevated 3
hours after treatment, and reached to the peak 6 hours after
treatment. IL-1b expression was also examined by western blotting
analysis. A remarkable upregulation of IL-1b was detected 3 hours
after TNF-a treatment. These results are consistent with the
reports from other investigators [33,34].
Resveratrol blocked TNF-a induced inflammation
Resveratrol is a potent Sirt1 agonist and increases Sirt1 activity
[18]. We employed resveratrol to investigate the anti-inflamma-
tion function of Sirt1. 3T3 fibroblasts were pretreated with
resveratrol followed by TNF-a challenge. Release of MMP-9 in
the culture media was observed in TNF-a treated cells and was
greatly inhibited by resveratrol in a dose dependent manner
(figure 2A). To test the time course of inflammatory inhibition by
resveratrol, resveratrol was administrated 1, 0 hour before or 1,
3 hours post TNF-a treatment, the relative mRNA levels of
inflammatory factors were detected by real-time RT-PCR
analysis at 9 hours after TNF-a treatment. Resveratrol inhibited
the pro-inflammatory factors in a clearly time-dependent fashion
(figure 2B). Upregulation of MMP-9, IL-6 and iNOS were
attenuated by resveratrol treated when resveratrol was employed
before or at the same time of TNF-a treatment. Induced IL-6
upregulation was inhibited even when resveratrol was employed 3
hours after TNF-a stimulation. Interestingly, lack of significant
inhibitory effect was observed when resveratrol was treated
1 hour (for iNOS) and 3 hours (for MMP-9) after TNF-a
stimulation. Furthermore, the TNF-a induced IL-1b expression
was also strikingly inhibited by resveratrol pretreatment for
1 hour (figure 2C). No cell death was observed within 72 hours
under these conditions (data not shown).
Resveratrol Inhibited inflammation via Sirt1
Since resveratrol is a pharmacological activator of Sirt1 and
may have off-target effects, we further examined whether Sirt1 is
required for anti-inflammatory activity of resveratrol. Sirt1
expression is induced by TNF-a or inflammation [35]. And
Sirt1 activity is highly related to its expression [36,37]. Here we
used RNA interference technique to knock down Sirt1 expres-
sion. Expression of Sirt1 was reduced 72 hours after treatment of
small interference RNA (siRNA) targeting Sirt1 gene (figure 3A).
Inhibitory effect of resveratrol on the upregulation of MMP-9,
IL-6 and iNOS was attenuated in the cells in which Sirt1
Resveratrol Inhibits TNF-a Induced Inflammation
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27081Figure 1. TNF-a induced overexpression of MMP-9, iNOS, IL-6 and IL-1b in 3T3/NIH fibroblasts. A. 3T3/NIH cells were incubated for 6, 24
or 48 hours (h) with varying concentrations of TNF-a, gelatin zymography were performed to detect MMP-9 expression in the medium. B. Cells were
treated by TNF-a (10 ng/ml) for 0, 1/2, 3, 6, 18 h, relative mRNA expressions of MMP-9, iNOS and IL-6 were examined by real-time RT-PCR analysis
(n=3 per group, *p,0.05 vs. 0 h; **p,0.01 vs. 0 h). C. Cells were treated by TNF-a for 0, 1/2, 3, 9, 24 h, IL-1b was measured by western blotting
analysis.
doi:10.1371/journal.pone.0027081.g001
Figure 2. Resveratrol inhibited TNF-a induced inflammation. A. 3T3/NIH cells were pretreated 1 h with varying concentrations of resveratrol
(Res) before TNF-a (10 ng/ml) treatment. MMP-9 expression in the medium was examined by gelatin zymography after 24 h treatment. B. Resveratrol
(50 nM) was used to treat cells 1, 0 hour before or 1, 3 hours post TNF-a (10 ng/ml), the relative mRNA levels of MMP-9, iNOS and IL-6 were detected
by real-time RT-PCR analysis at 6 hours post TNF-a treatment. (n=3 per group, *p,0.05 vs. TNF-a+/Res-; **p,0.01 vs. TNF-a+/Res-). C. Cells were
pretreated by resveratrol 1 h before TNF-a, western blotting analysis was used to detect IL-1b expression after 9 h treatment.
doi:10.1371/journal.pone.0027081.g002
Resveratrol Inhibits TNF-a Induced Inflammation
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that anti-inflammation of resveratrol is mainly dependent on
Sirt1 and Sirt1 exerts a negative regulatory effect on the
inflammation.
Resveratrol decreased acetylated RelA/p65
NF-kB plays a central role in inflammation [38]. Acetylasion of
NF-kB subunit RelA/p65 at Lysine310 is involved in the activity
of NF-kB and inflammatory factors transcription [39]. We found
that TNF-a increased acetyl-NF-kBp65 (Lysine310) and resvera-
trol suppressed NF-kBp65 acetylation in 3T3 cells (figure 4A-B).
To explore whether the deacetylatic function of resveratrol is also
Sirt1 dependent, Sirt1 was knocked down by siRNA. Interestingly,
basal level of acetyl-NF-kBp65 (Lys310) was increased after Sirt1
knockdown. Inhibitory effect of resveratrol on the acetyl-NF-
kBp65 was diminished by Sirt1 knockdown (figure 4C). The
results indicate that Sirt1 is required for inhibiting NF-kBp65
acetylation by resveratrol. It also suggests that Sirt1 plays a role in
regulation of RelA/p65 acetylation.
Resveratrol inhibited activation of mTOR induced by
TNF-a
Mammalian target of rapamycin is related to TNF-a induced
inflammation [40]. In this study, upregulation of phosphorylated
mTOR and S6RP were detected as early as 30 minutes and
returned back to control level within 24 hours after TNF-a
stimulation (figure 5A). We also found that resveratrol suppressed
phosphorylated mTOR and S6RP (figure 5B) and further reduced
the expression of IL-1b and MMP-9 (figure 5 B–C). Moreover,
rapamycin inhibited phosphorylation of mTOR and S6RP, and
suppressed MMP-9 and IL-1b upregulation (figure 5 B–C).
Discussion
Previous studies have revealed that resveratrol activates Sirt1
and suppresses the inflammation of both in vivo and in vitro
experiment models [20,21,36,41]. In the present study, we found
that TNF-a induced upregulation of cytokines and MMP-9 in 3T3
fibroblasts. Sirt1 was constitutively expressed in the cells and
upregulated after TNF-a treatment. Resveratrol inhibited TNF-a
induced overexpression of cytokines, iNOS and MMP-9 via Sirt1
dependent manner. Knockdown of Sirt1 caused increase of IL-6,
iNOS and MMP-9 expression. The anti-inflammation function of
resveratrol was blocked after Sirt1 knockdown. This study suggests
that resveratrol ameliorates inflammation via activating Sirt1.
Reduction of acetylated NF-kB and suppression of mTOR/S6RP
phosphorylation may be involved in the mechanisms.
TNF-a has been demonstrated to be one of the main
inflammatory mediators that involved in autoimmune diseases,
such as rheumatoid arthritis, systemic sclerosis [2,42]. TNF-a
initiates or aggravates inflammation by activating NF-kB and
producing cytokines, chemokines, MMPs, and other inflammatory
molecules in different types of cells [20,32]. In the present study,
we found that TNF-a induced MMP-9, IL-6, and iNOS in a dose-
and time-dependent fashion without causing cell death in
fibroblasts. These findings are consistent with other reports
[20,21]. We applied this in vitro model to further investigate the
role of Sirt1 in TNF-a induced inflammation.
Sirt1 plays a critical role in regulation of several transcription
factors such as p53, NF-kB and FoxOs and has many important
functions in metabolism, anti-cancer, anti-ageing and anti-
inflammation [12,13,43,44]. Overexpression of Sirt1 or increase
of Sirt1 activity significantly suppresses cytokines production and
reduces inflammation in different animal models [20,21]. On the
Figure 3. Resveratrol Inhibited inflammation in a Sirt1 dependent manner. A. Western blotting analysis shows Sirt1 siRNA (20 nM)
transfection for 72 hours strikingly blocked Sirt1 expression, compared to control (Cont) siRNA (20 nM) or DDW transfection. B. After Sirt1 or control
siRNA transfection for 72 h, cells were h pretreated with resveratrol (50 nM) in the presence of TNF-a (10 ng/ml) treatment for 24 h, MMP-9
expression in the medium were examined by gelatin zymography. C. Cells were processed as (B) for 6 h, real-time RT-PCR analysis was used to
examine mRNA expression of MMP-9, IL-6, iNOS (n=3 per group, *p,0.05 vs. Sirt1 siRNA-; **p,0.01 vs. Sirt1 siRNA-).
doi:10.1371/journal.pone.0027081.g003
Resveratrol Inhibits TNF-a Induced Inflammation
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inflammatory response [45,46]. It has been shown that TNF-a
induces inflammation through activation of cathepsin B followed
by cleavage of Sirt1 [47]. More severe encephalomyelitis and
autoimmunity induced by myelin oligodendroglia glycoprotein
(MOG) peptide is detected in Sirt1-deficient mice compared to the
controls [48]. MMP-9 expression in Sirt1-/- mouse embryonic
fibroblasts (MEF) is significant higher than that in wild type cells
[49]. Our data showed that Sirt1 was constitutively expressed in
the 3T3 fibroblasts (figure 3A). Knockdown of Sirt1 caused
increase of MMP-9, iNOS and IL-6 expression. Similar
phenomenon is also observed in vascular smooth muscle cells.
The inhibitory effect on AP-1, c-Jun or c-Fos by Sirt1 might be the
potential mechanism [48,50]. These results suggest that Sirt1 plays
a role in suppressing expression of inflammatory molecules even
under normal conditions.
Resveratrol is a potent activator of Sirt1 and has multiple effects
on metabolism, anti-cancer, anti-ageing and anti-inflammation
[11,19,51,52]. Treatment of resveratrol suppresses cyclooxygen-
ase-2 activity [53] and modulates interferon-gamma (IFN-c),
TNF-a, IL-6 and MCP-1 expression in experimental ileitis [54]. In
cultured neural cells, resveratrol prevents increase of cytokines,
chemokines and iNOS/NO induced by lipopolysaccharide (LPS)
[55]. In IL-1b treated human chondrocytes, resveratrol inhibits
the cytokine production [22]. Furthermore, resveratrol ameliorates
LPS induced inflammatory arthritis in vivo [24]. In this study, we
observed that resveratrol significantly inhibited the TNF-a
induced increase of MMP-9, IL-6, iNOS and IL-1b in the
fibroblasts. The inhibitory effect was in a dose- and time-
dependent fashion. The evidence indicates that resveratrol is an
efficient inhibitor of inflammation in fibroblasts.
Although resveratrol is a pharmacological agonist of Sirt1 and
may have multiple targets, several studies indicate that the anti-
inflammatory function of resveratrol is highly dependent on Sirt1
[51,56]. Resveratrol upregulates Sirt1 expression at both tran-
scriptional and translational level [57,58]. Furthermore, by
binding to Sirt1, resveratrol alters Sirt1 structure and upregulates
its activity as much as 8 folds, and lowers the Km value for
acetylated substrate [11,18]. However, other studies suggest that
resveratrol may not directly activate Sirt1 [59,60]. Resveratrol
lacks inhibition of upregulation of hypoxia induced factor 1 alpha
(HIF-1a) and AMP-activated protein kinase (AMPK) in the cells in
which Sirt1 is deficit [61]. Reduction of MMP-9 expression by
resveratrol is remarkably attenuated in Sirt1-/- mouse embryonic
fibroblasts (MEF) [49]. But the inhibitory effect of resveratrol on
Smad2/3 phosphorylation was reported to be independent of Sirt1
[62,63]. In the present study, suppression of TNF-a-induced
inflammatory response by resveratrol was attenuated in the cells in
which Sirt1 was knocked down by RNA interference. Our findings
support that Sirt1 is required for anti-inflammation of resveratrol
and suggest that Sirt1 is an important target for treatment of
autoimmune disorders.
Several lines of evidence indicate that NF-kB is one of Sirt1
targets. NF-kB acetylation is critical for its activity, especially in
cytokines induced inflammation [64]. Acetylation of NF-kBa t
Figure 5. mTOR/S6RP is also involved in the inhibitory function
of resveratrol on TNF-a induced inflammation. A. 3T3/NIH cells
were treated with TNF-a (10 ng/ml) for 0, 1/2, 3, 9, 24 h, phosphory-
lation of mTOR and S6RP was detected by western blotting analysis.
B. Cells were pretreated by rapamycin (Rapa, 10 ng/ml) or resveratrol
(50 nM) for 1 h in the presence of TNF-a treatment for 24 h, MMP-9
released in medium was measured by gelatin zymography. C. Cells
were processed as (B) for 3 h, IL-1b and phosphorylation of mTOR and
S6RP were examined by western blotting analysis in cell lysis.
doi:10.1371/journal.pone.0027081.g005
Figure 4. Resveratrol decreased acetylated RelA/p65. A. 3T3/NIH
cells were treated with TNF-a (10 ng/ml) for 0, 1/2, 3, 9, 24 h, and
acetyl-NF-kBp65(Lys310) (acetyl-p65) expression was detected by
western blotting analysis in cell lysis. B. Cells were pretreated by
resveratrol (50 nM) in the presence of TNF-a treatment for 3 h, acetyl-
NF-kBp65(Lys310) expression were examined by western blotting
analysis. C. Cells were transfected with Sirt1 or control siRNA for
72 h, then pretreated with resveratrol (50 nM) in the presence of TNF-a
(10 ng/ml) treatment for 3 h. Western blotting analysis was used to
detect acetyl-NF-kBp65(Lys310) expression.
doi:10.1371/journal.pone.0027081.g004
Resveratrol Inhibits TNF-a Induced Inflammation
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increased accessibility to transcription factor binding which
contributes to pro-inflammatory factors production [65,66]. Sirt1
physically interacts with the RelA/p65 subunit of NF-kB and
inhibits transcription by deacetylation of RelA/p65 at lysine 310
[15,67]. Acetylation of RelA/p65 at lysine 310 has been reported
to be required for full transcriptional activity of NF-kBi n
inflammation [68]. In this study, we found that TNF-a increased
acetylation at Lysine 310 of RelA/p65 subunit. Resveratrol
inhibited the TNF-a induced acetylation of RelA/p65 via a
Sirt1-dependent manner (figure 4). Our findings further support
the elucidation of the mechanism that the inhibitory effect of Sirt1
is due to suppressing NF-kB activity.
Mammalian target of rapamycin (mTOR) is a serine/threonine
protein kinase which regulates protein synthesis [69,70]. Studies
report that activation of mTOR plays a role in TNF-a-induced
inflammatory cascades [71], and is also implicated in inflamma-
tion related diseases [72]. TNF-a increases phosphorylation of
mTOR and its downstream targets p70S6K and S6RP [73,74,75].
Rapamycin ameliorates inflammation by inhibiting mTOR and
further decreasing expression of cytokines and chemokines,
improves outcomes in inflammation related disease models
[76,77]. These results suggest that mTOR is an important target
for treatment of inflammation. In the present study, mTOR and
S6RP were phosphorylated and activated in TNF-a stimulated
fibroblasts. Resveratrol also notably downregulated the phosphor-
ylated mTOR and S6RP while ameliorating the inflammation in
fibroblasts, suggesting that inhibition of mTOR may be one of the
mechanisms of its anti-inflammatory effect.
In summary, our results indicate that Sirt1 plays a key role in
inflammation. Activation of Sirt1 by its agonists such as resveratrol
efficiently suppresses inflammatory cascades. This study provides
an insight for developing therapeutic approaches for inflammation
related diseases or autoimmune disorders. Further investigation in
animal models is warranted to confirm the findings from in vitro
studies.
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